Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...